Optimizing Levothyroxine Dosage for Patients After Thyroid Surgery
Patient-centered Decision Support Tool for Levothyroxine Dosage
This study is testing a new tool that helps find the right dose of levothyroxine faster for people who have had their thyroid removed, to see if it improves their health and ability to work compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital of North Norway Academic / other |
| Locations | 3 sites (Bergen and 2 other locations) |
| Trial ID | NCT06455371 on ClinicalTrials.gov |
What this trial studies
This study evaluates a decision support tool designed to predict the optimal dosage of levothyroxine for patients who have undergone total thyroidectomy. By analyzing repeated blood samples within the first two weeks of therapy, the tool aims to facilitate quicker dosage adjustments compared to the standard practice of adjusting every two months. The study will compare the outcomes of patients using this tool against those receiving conventional care, focusing on patient-reported outcomes and work ability.
Who should consider this trial
Good fit: Ideal candidates are patients who have had a total thyroidectomy for differentiated thyroid cancer or benign thyroid nodules.
Not a fit: Patients with anaplastic thyroid cancer, thyroid cancer with distant metastasis, Graves' disease, toxic nodules, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to faster and more effective management of levothyroxine therapy, improving patient quality of life.
How similar studies have performed: While the use of decision support tools in medication management is gaining traction, this specific approach for levothyroxine dosage adjustment is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals Exclusion Criteria: * Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy
Where this trial is running
Bergen and 2 other locations
- Haukeland University Hospital — Bergen, Norway (Recruiting)
- Oslo University Hospital — Oslo, Norway (Recruiting)
- University Hospital of North Norway — Tromsø, Norway (Recruiting)
Study contacts
- Study coordinator: Vegard Brun, PhD
- Email: vegard.heimly.brun@unn.no
- Phone: 0047 77669260
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.